Introduction: Pregnancy and postpartum are periods of increased vulnerability for some psychiatric disorders. Recent studies reveal a prevalence of mental illness that reaches 14% during both periods, with mood and anxiety disorders being the most frequent, specially during the 1st and 3rd quarters [1]. When left untreated, psychiatric disorders imply serious consequences for the pregnant woman and the fetus, namelly higher maternal mortality as well as higher occurrence of spontaneous abortion, prematurity and lower weight at birth. It may also imply deficient nutrition and maternal care, dificulties on the bounding process and delay of psychomotor development. Thus, early clinical evaluation and appropriate treatment, are essential during this period. Since 1995, the Psychiatric Liaison Consultation in Bissaya Barreto Maternity integrates the Early Intervention Unit (UIP), which is formed by a multidisciplinary team that ensures a specific intervention in pregnancy and postpartum periods in women with psychiatric illness. This multidisciplinary team includes psychiatrist, obstetrician, nurses, social workers and psychologist. Purpose of the Study: Compare neonatal outcomes of pregnant women exposed to psychotropic drugs for sleep disorders during pregnancy, with and without Depressive symptomatology, with pregnant women without psychiatric symptomatology and not exposed to any therapy during pregnancy. Methodology: The authors conducted a case–control study to compare neonatal outcomes between pregnant women exposed to psychotropic drugs for sleep disorders (antidepressants, antipsychotics and benzodiazepines), observed at the Psychiatry– Obstetric Consultation (study group), and pregnant women followed at the Obstetric Consultation, without psychopathology during pregnancy, therefore not exposed to psychiatric medication (control group). The authors assessed the study group for the presence of psychopathology, focusing on the presence of sleep disorders and its correlation with the presence of depressive disorders. Several data were collected from the clinical processes and include the type and the dosage of psychotropic drug prescribed, Apgar scores at birth, weight at birth, type of delivery, gestational age at delivery and other relevant clinic parameters, like neonatal complications. During pregnancy, all women of both groups underwent ultrasound monitoring quarterly, with biometry. The study has 6 months of duration (January 2014 to July 2014). Results: Data were analyzed using the Statistical Package for the Social Sciences − SPSS (19th version). A p value lower than 0.05 indicates statistical significance for a particular variable. Conclusions: Obstetrical and neonatal outcomes in the group exposed to psychiatric medication are as good as in the control group, supporting that the use of psychotropic drugs during pregnancy is safe to the mother and the baby, as long as used with caution. Early psychiatric intervention during pregnancy, in conjunction with obstetrics, is the gold standard to follow up pregnant women with mental illness and the results this study will bring more development to an area that still offers some controversy.